On 5 February 2021 we published a clarification to this piece. It is available here. Five weeks ago, when I raised questions about the results of Pfizer’s and Moderna’s covid-19 […]
Only full transparency and rigorous scrutiny of the data will allow for informed decision making, argues Peter Doshi […]
Four years ago, the US National Institutes of Health (NIH) launched a pilot project to “leverage the social power of the internet to encourage constructive criticism and high quality discussions.” The service […]
In the late 1980s, AIDS activists stormed the headquarters of the US Food and Drug Administration (FDA) with a message that the FDA’s drug approval process was, simply put, killing […]
Health Canada seems to want to have it both ways: be seen as a regulator that serves the public interest through a progressive commitment to transparency, yet be trusted by […]
“Thirdly, we will post the protocol of our trials as they are started and the results of trials once they are completed on two websites which are available to the […]
In late 2010, the European Medicines Agency (EMA) became the first regulator in history to promulgate a freedom of information policy that covered the release of manufacturer submitted clinical trial […]
It’s hard to imagine a restaurant without a menu, a sheet where the fare is listed, where the ingredients are explained, and limitations are clearly labelled (“not for people with […]
Yesterday’s announcement that the EMA Management Board may have adopted a less obstructive policy to releasing clinical trial data comes hard on the heels of widespread coverage (see here, here, […]
The FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines, says Peter Doshi […]
